title: Percutaneous coronary interventions in octogenarians: Acute and 12 month results in a large single-centre experience.
abstract: OBJECTIVE
  To review the results of PCI in patients aged >or=80 years.
  
  
  BACKGROUND
  Octogenarians represent a growing proportion of patients treated with PCI; in this subset of high-risk patients, the role of complete revascularization is still controversial.
  
  
  METHODS
  We examined in-hospital, 30 days, and 12-month events in 356 patients aged >or=80 years submitted to PCI from 2004 to 2006 and 754 patients aged <80 years treated in 2006.
  
  
  RESULTS
  Octogenarians had a higher risk profile. A complete revascularization was obtained in 48% of them and in 65% of younger patients (P < 0.001); glycoprotein IIb/IIIa inhibitors (GPI) use was common in both groups (43 vs. 46.5%). In-hospital mortality was higher in octogenarians (3.9 vs. 1.3%, P = 0.01) as well as vascular complications (2.8 vs. 1%, P = 0.058). Mortality resulted 5.9 vs. 1.2% at 30 days (P < 0.001), and 16.3 vs. 3.9% at 12 months (P <0.001) in the two groups whereas repeat revascularization procedures did not differ (9.3 vs. 8.4%, respectively). In patients aged >or=80, there was no difference in 12 months total events (20 vs. 28%, P = 0.07) and repeat revascularizations (8 vs. 10%, P = 0.498) in completely or uncompletely revascularized subjects. At multivariate analysis age (P = 0.002), diabetes (P = 0.002), three vessel disease (P = 0.020) and procedural success (P = 0.002) were independent predictors of total events at 12 months.
  
  
  CONCLUSIONS
  In our experience, frequent GPI use and multivessel PCI in 41% of >or=80 years-old patients resulted in good immediate and mid-term clinical outcomes, irrespective of the completeness of revascularization achieved.
authors.affiliation: Department of Cardiology, S. Maria delle Croci Hospital, Ravenna, Italy. ra.hocardioemo@ausl.ra.it
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Varani
authors.forename: Matteo
authors.initials: M
authors.lastname: Aquilina
authors.forename: Marco
authors.initials: M
authors.lastname: Balducelli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Vecchi
authors.forename: Valeria
authors.initials: V
authors.lastname: Frassineti
authors.forename: Aleardo
authors.initials: A
authors.lastname: Maresta
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D023921:Coronary Stenosis / Q000401:mortality / Q000628:therapy*; D048909:Diabetes Complications / Q000628:therapy; D005260:Female; D006299:Health Services for the Aged; D017052:Hospital Mortality; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex